- Home
- WF vs ROIV Comparison
WF vs ROIV Comparison
Compare WF & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WF | ROIV |
|---|---|---|
| Founded | 1899 | 2014 |
| Country | South Korea | United Kingdom |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WF | ROIV |
|---|---|---|
| Price | $59.21 | $21.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $24.31 |
| AVG Volume (30 Days) | 54.5K | ★ 8.2M |
| Earning Date | 10-29-2025 | 02-09-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ 20.51 | N/A |
| EPS | ★ 2.97 | N/A |
| Revenue | ★ $8,054,512,650.00 | $20,329,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.37 | $741.42 |
| P/E Ratio | $6.55 | ★ N/A |
| Revenue Growth | ★ 23.56 | N/A |
| 52 Week Low | $29.44 | $8.73 |
| 52 Week High | $60.48 | $23.47 |
Technical Indicators
Market Signals| Indicator | WF | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 61.11 | 51.68 |
| Support Level | $58.35 | $20.78 |
| Resistance Level | $60.48 | $22.21 |
| Average True Range (ATR) | 1.02 | 0.69 |
| MACD | 0.05 | -0.17 |
| Stochastic Oscillator | 74.78 | 30.46 |
Price Performance
Historical ComparisonAbout WF Woori Financial Group Inc. (each representing three (3) shares of)
Woori Financial Group Inc is a banking and financial services holding company that offers a wide range of services, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, and other businesses. The operating segments of the company include Banking, Credit card, Capital, Investment banking, and others.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.